title: Clinical significance of serum soluble interleukin-2 receptor-α in extranodal natural killer/T-cell lymphoma (ENKTL): a predictive biomarker for treatment efficacy and valuable prognostic factor.
abstract: Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is an aggressive disease, and no standard treatment and validated prognostic model were established. Serum sIL-2Rα levels were measured in 94 ENKTL patients to evaluate its relationship with clinical features, treatment response, and prognosis. Serum sIL-2Rα level was 2964 ± 1613.6 ng/L in ENKTL patients, higher than in normal healthy controls (p < 0.05). Using median level (2508.5 ng/L) as cutoff, patients were divided into higher- and lower-level group (N = 47 for each). The complete remission and overall remission rate were significantly higher in lower-level group (p < 0.05). After a median follow-up time of 22.0 months, 2-year overall survival and progression-free survival rates were 60.0 and 53.0 %, respectively. Lower sIL-2Rα level significantly correlated with better progression-free survival (PFS) and overall survival (OS) (p = 0.001 and 0.002, respectively). IPI score and treatment responses after 2 cycles of chemotherapy significantly correlated with PFS and OS (p < 0.05). In a multivariate Cox regression model that included IPI score, treatment responses, and sIL-2Rα level, all three parameters were independent prognostic factors for OS (p = 0.043, 0.001, and 0.025, respectively), and the last two parameters were also independent factors for PFS (p = 0.005 and 0.005, respectively). Elevated serum sIL-2Rα level was related to poor responses to treatments and can be used as a valuable biomarker for disease activity. Moreover, serum sIL-2Rα was an independent prognostic factor for both OS and PFS. These results need to be validated in prospective trials and may support the incorporation of anti-CD25 targeted therapy into the treatment realm of ENKTL.
authors.affiliation: Department of Hematological Oncology, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, People's Republic of China.
authors.forename: Liang
authors.initials: L
authors.lastname: Wang
authors.forename: Ding-zhun
authors.initials: DZ
authors.lastname: Liao
authors.forename: Jing
authors.initials: J
authors.lastname: Zhang
authors.forename: Zhong-jun
authors.initials: ZJ
authors.lastname: Xia
authors.forename: Xiong-wen
authors.initials: XW
authors.lastname: Peng
authors.forename: Yue
authors.initials: Y
authors.lastname: Lu
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053645:Interleukin-2 Receptor alpha Subunit / Q000097:blood*; D054391:Lymphoma, Extranodal NK-T-Cell / Q000097:blood* / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D015996:Survival Rate
chemical_list: D014408:Biomarkers, Tumor; D053645:Interleukin-2 Receptor alpha Subunit
references.citation: Science. 1986 May 9;232(4751):727-32
references.pmid: 3008337
references.citation: Am J Hematol. 1994 Jul;46(3):179-83
references.pmid: 7514848
references.citation: Cancer. 2013 Jan 15;119(2):348-55
references.pmid: 22811078
references.citation: Cancer Immunol Immunother. 1991;33(3):198-202
references.pmid: 2044083
references.citation: J Clin Oncol. 1999 Apr;17(4):1244
references.pmid: 10561185
references.citation: Int J Hematol. 2012 Nov;96(5):617-23
references.pmid: 22983648
references.citation: Br J Cancer. 1998 Jun;77(11):1820-4
references.pmid: 9667652
references.citation: Leuk Lymphoma. 2011 Jun;52(6):1041-8
references.pmid: 21599590
references.citation: Blood. 2012 Oct 11;120(15):2973-80
references.pmid: 22919026
references.citation: Am J Surg Pathol. 2012 Apr;36(4):481-99
references.pmid: 22314189
references.citation: Blood. 1990 Jan 15;75(2):434-44
references.pmid: 2153036
references.citation: Blood. 1988 Apr;71(4):1135-7
references.pmid: 3128348
references.citation: Ann Hematol. 2012 Aug;91(8):1265-70
references.pmid: 22373550
references.citation: Am J Hematol. 2008 Sep;83(9):747-9
references.pmid: 18615554
references.citation: Chest. 1991 Jun;99(6):1433-7
references.pmid: 2036827
references.citation: Blood. 2011 Feb 10;117(6):1834-9
references.pmid: 21123825
references.citation: J Invest Dermatol. 2006 Mar;126(3):575-83
references.pmid: 16410787
references.citation: J Clin Oncol. 2008 Sep 1;26(25):4124-30
references.pmid: 18626005
references.citation: Blood. 1993 Jan 15;81(2):424-9
references.pmid: 8422462
references.citation: Ann Intern Med. 1990 Oct 15;113(8):619-27
references.pmid: 2205142
references.citation: Pediatr Blood Cancer. 2007 Feb;48(2):124-31
references.pmid: 16937360
references.citation: J Clin Oncol. 2011 Nov 20;29(33):4410-6
references.pmid: 21990393
references.citation: Cancer. 1991 Apr 15;67(8):2180-5
references.pmid: 1848475
references.citation: Clin Cancer Res. 2009 Apr 15;15(8):2905-12
references.pmid: 19318493
references.citation: Blood. 2011 Dec 1;118(23):6018-22
references.pmid: 21984805
references.citation: Blood Rev. 2007 Sep;21(5):245-53
references.pmid: 17590250
references.citation: J Clin Oncol. 2006 Feb 1;24(4):612-8
references.pmid: 16380410
references.citation: Eur J Haematol. 2001 Jan;66(1):24-30
references.pmid: 11168504
references.citation: Blood. 2005 Dec 1;106(12):3785-90
references.pmid: 16109779
references.citation: Science. 1988 May 27;240(4856):1169-76
references.pmid: 3131876
references.citation: Biomarkers. 2008 Feb;13(1):1-26
references.pmid: 17906988
references.citation: Blood. 2011 Sep 8;118(10):2809-20
references.pmid: 21719603
references.citation: Am J Hematol. 2008 Oct;83(10):795-9
references.pmid: 18756548
references.citation: Ann Oncol. 2009 Mar;20(3):526-33
references.pmid: 19074749
references.citation: Clin Lymphoma Myeloma Leuk. 2013 Aug;13(4):410-6
references.pmid: 23747081
references.citation: Clin Cancer Res. 2000 Apr;6(4):1445-51
references.pmid: 10778976
references.citation: Cancer Immunol Immunother. 1994 Mar;38(3):160-6
references.pmid: 7907273